PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143348
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143348
Medical Device Viral Inactivation Testing market size was valued at US$ 210.7 Million in 2025, expanding at a CAGR of 18.1% from 2026 to 2033.
Medical device viral inactivation testing is an important validation step that is performed on medical devices that come into contact with bodily fluids and tissue in order to assess whether the medical device is able to inactivate any viruses. If the medical device can effectively prove viral inactivation, there is increased assurance that patient infections will not occur due to the use of the device. It is an important factor to regulatory and manufacturing bodies that need to ensure that their products have effective infection control measures. The process ensures that viral load within the patient environment is lowered to a safe level. This testing strengthens infection control, regulatory compliance, and confidence in medical device safety.
Medical Device Viral Inactivation Testing Market- Market Dynamics
Expansion Of Complex And Minimally Invasive Medical Devices To Drive Market Demand
The expansion of complex and minimally invasive medical devices is expected to drive the Medical Device Viral Inactivation Testing market forward. This helps in the prevention of any kind of infections or contamination in such devices, especially by dangerous viruses. For example, in January 2026, according to the U.S. International Trade Administration (Trade Gov), the revenue of the medical technology industry in the UK stands at around $35,800 million (USD), employing more than 138,000 employees, and there are more than 4,000 medical technology firms working in the UK, most of which are SMEs (over 85%). Moreover, the number of medical technology companies has grown by more than 200% in the past ten years.
The National Health Service (NHS) contributes to 85% of the health care in the UK and spends an average of $6,600 million (USD) annually on clinical products that comprise medical technology. The spending of the NHS on medical technology is mostly related to implants and prosthetics; surgical, laboratory, IV, cardiovascular, and anesthesia equipment; radiology; and patient monitoring technologies. This trend is expected to strengthen demand for viral inactivation testing across advanced medical devices.
The Global Medical Device Viral Inactivation Testing market is segmented on the basis of Virus Type, Testing Method, Application, and Region.
Among the given virus types, enveloped viruses account for a prominent share of these viruses as model viruses used in viral inactivation validation studies and are susceptible to common antiviral drugs. It becomes easier to establish the safety of viruses in medical device manufacturing and sterilization processes. In July 2025, Eurofins BioPharma Product Testing Italy offered more viral clearance services in their Milan facility because of viral inactivation tests and viral removal tests on the biologics and medical devices in the medical device industry. This trend is expected to strengthen demand for enveloped virus testing in viral safety validation.
In the Medical Device Viral Inactivation Testing market, the biocompatibility testing segment represents a key testing method segment, as it provides for the safety and biological safety characteristics of a medical device prior to its launch into the market or any clinical trials and is also useful for manufacturing companies in meeting the requirements of regulatory authorities. In July 2025, NAMSA published a new report on biological testing methods for medical devices, emphasizing the biocompatibility testing in accordance with ISO 10993. The report stresses the importance of the risk-based biological evaluation of medical devices that includes chemical characterization and biological testing of the medical device depending on its application and contact. These activities support manufacturers in identifying biological risks and establishing appropriate testing strategies for regulatory submissions.
Medical Device Viral Inactivation Testing Market- Geographical Insights
North America maintains a key position in the global Medical Device Viral Inactivation Testing market, which is explained by the presence of high-quality guidelines and regulatory standards in the region. For instance, in February 2026, according to the U.S. Food and Drug Administration (Gov), the market is made up of 3 major types of devices. These include class I, class II, and class III. Class I to class III show a gradual increase in the regulatory control of devices. Most Class I devices are placed under the exempt category in regard to the need for 510 (k) premarket notification. Most class II devices need 510(k) clearance, while most class III devices require PMA. In addition, the FDA has 7 major requirements for the medical devices available in the United States.
These include establishment registration, device listing, 510(k) or PMA, Investigational Device Exemption (IDE), Quality Management System Regulation (QMSR), labeling, and Medical Device Reporting (MDR). There are 12 FDA-accredited third-party reviewers that cover 670 devices altogether. The FDA has an obligation to give its determination in 30 days after a recommendation by the accredited persons. This regulatory rigor strengthens North America's position as a key market for viral inactivation testing.
The global Medical Device Viral Inactivation Testing market, which is globally present, has a competitive landscape that is quite diversified and includes both testing service providers and contract laboratories. Some of the major players that are part of the market and provide not just solutions but also testing facilities and also cater to the safety aspects of the medical device sector include Charles River, Perfectus Biomed (NAMSA), Eurofins Scientific, Nelson Labs, and Texcell. The market has the potential to innovate further, considering the increasing biosafety standards and advanced testing capability, among other factors. In January 2026, Charles River Laboratories announced that it intends to purchase the balance approximate 79% equity interest in PathoQuest SAS for approximately USD 60 million, enhancing its advanced next-generation sequencing technology for biopharmaceutical quality control and biosafety testing. The market is poised for continued innovation, driven by expanding biosafety requirements and advanced testing capabilities.
In March 2025, Nelson Labs introduced the Rapid Sterility Testing process, applying rapid microbiological techniques to shorten the time required to conduct product sterility tests to just 6 days, from the usual 14-day incubation period, in the medical device and pharmaceutical industries.